Branded Rx · FDA-approved for chronic weight management
FDA-approved tirzepatide, indicated for chronic weight management.
Zepbound is the FDA-approved branded tirzepatide indicated specifically for chronic weight management in adults with obesity or overweight with weight-related conditions. Manufactured by Eli Lilly. At Cypress, you pay up front and submit to your insurance for reimbursement.
Why Zepbound specifically
Zepbound and Mounjaro share an active ingredient (tirzepatide) but have different FDA-approved indications. Zepbound is approved for chronic weight management. For some insurance plans, the indication on the prescription matters — coverage rules differ.
If your insurance plan has clear coverage criteria for chronic weight management, Zepbound can be the more reimbursable choice. Your clinician will help you decide.
Cypress is not affiliated with Eli Lilly. Zepbound is a registered trademark of its respective owner.
How Cypress branded works
Side effects & safety
Most common: nausea, decreased appetite, mild diarrhea, constipation, fatigue.
Less common but important: pancreatitis, gallbladder issues, low blood sugar.
Not appropriate if: personal/family history of medullary thyroid carcinoma or MEN2; pregnant, planning pregnancy, or breastfeeding; severe GI or end-stage organ disease.
The 3-minute medical screener is free. We'll ask about your insurance early.
Start your assessment